ESC Professional Premium Access

Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

Congress Presentation

About the speaker

Doctor Rodrigo Alonso

Center for Advanced Metabolic Medicine and Nutrition, Santiago (Chile)
0 follower

6 more presentations in this session

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Speaker: Doctor A. Cordero (Sant Joan d'Alacant, ES)


Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients

Speaker: Doctor J. Katzmann (Leipzig, DE)


Effect of SLCO1B1 genotypes on statin intolerance and response to statins

Speaker: Mrs L. Davis (Harefield, GB) Doctor T. Khan (Harefield, GB)


LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study

Speaker: Professor K. Ray (London, GB)


Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease

Speaker: Doctor D. Vikulova (Vancouver, CA)


Access the full session

Lipids - Drug therapy 2

Speakers: Doctor R. Alonso, Doctor A. Cordero, Doctor J. Katzmann, Mrs L. Davis, Doctor T. Khan...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk